<!DOCTYPE html>
<html>
<head>
    <title>PressReader - The Straits Times: 2020-07-21 - Ox&#xAD;ford-As&#xAD;traZeneca vac&#xAD;cine study shows dual im&#xAD;mune ac&#xAD;tion</title>
    <meta name="description" content="">
    <meta content="magazines, newspapers, digital news, reading, news, breaking news, newspaper online" name="keywords">
    <meta name="Robots" content="NOARCHIVE,NOODP">
    <meta charset="UTF-8">
    <meta http-equiv="Content-type" content="text/html; charset=utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    
    <link rel="canonical" href="/singapore/the-straits-times/20200721/281758451602137" />


    <style>
        li {
            margin: 1em 0;
        }
        img {
            max-width: 100%;
        }
        p, h1, h2, h3 {
            max-width: 100%;
        }
    </style>
</head>
<body>
    <div>
        

<article>
    <h1>Ox&#xAD;ford-As&#xAD;traZeneca vac&#xAD;cine study shows dual im&#xAD;mune ac&#xAD;tion</h1>
    <h2></h2>
    <section>
        <a href="/singapore/the-straits-times/textview" title="The Straits Times">The Straits Times</a>
        - <a href="/singapore/the-straits-times/20200721/textview" title="The Straits Times - 2020-07-21"><time>2020-07-21</time></a>
        - <span>TOP OF THE NEWS</span>
        - <span role="byline"></span>
    </section>

    <p>LON­DON • A coro­n­avirus vac­cine the Univer­sity of Ox­ford is de­vel­op­ing with Bri­tish-Swedish drug­maker As­traZeneca showed promis­ing re­sults in early hu­man test­ing, a sign of progress in the high-stakes pur­suit of a shot to de­feat the pathogen.</p>
    <p>The vac­cine in­creased lev­els of both pro­tec­tive neu­tral­is­ing an­ti­bod­ies and im­mune T-cells that tar­get the virus, ac­cord­ing to the study or­gan­is­ers.</p>
    <p>The re­sults were pub­lished yes­ter­day in The Lancet med­i­cal jour­nal.</p>
    <p>“We are see­ing very good im­mune re­sponses, not just on neu­tral­is­ing an­ti­bod­ies but of T-cells as well,” said Pro­fes­sor Adrian Hill, head of Ox­ford’s Jen­ner In­sti­tute, in an in­ter­view.</p>
    <p>“We’re stim­u­lat­ing both arms of the im­mune sys­tem.”</p>
    <p>The pro­posed vac­cine is made from a weak­ened ver­sion of a com­mon cold virus that is ge­net­i­cally changed to make it un­able to grow in hu­mans.</p>
    <p>The harm­less virus will carry some of the pathogen’s ge­netic ma­te­rial into cells to gen­er­ate an im­mune re­sponse.</p>
    <p>The Ox­ford sci­en­tists have in­serted ge­netic ma­te­rial from the sur­face spike pro­tein of the Sars-CoV-2 virus – a cru­cial tool to in­vade our cells – as a way of trick­ing the im­mune sys­tem into fight­ing back.</p>
    <p>The plat­form stim­u­lates both an­ti­bod­ies and high lev­els of killer Tcells, a type of white blood cell that helps the im­mune sys­tem de­stroy in­fec­tion.</p>
    <p>Prof Hill said that while the test does not prove the vac­cine will work, “I think we’re a bit more con­fi­dent it should work this week than last week”.</p>
    <p>The Ox­ford shot elicited neu­tral­is­ing an­ti­bod­ies af­ter a sin­gle dose, which may be an im­por­tant ad­van­tage in quickly rais­ing im­mu­nity.</p>
    <p>Across the world, about 160 coro­n­avirus vac­cines are in var­i­ous stages of de­vel­op­ment, ac­cord­ing to the World Health Or­gan­i­sa­tion, and the Ox­ford shot is close to the front of the pack.</p>
    <p>US biotech firm Moderna, China’s Si­no­vac Biotech and Si­nopharm are also de­vel­op­ing their own vac­cines.</p>
    <p>Si­nopharm, which is work­ing with the United Arab Emi­rates on tri­als, has re­port­edly fin­ished con­struc­tion of a new pro­duc­tion fa­cil­ity with a ca­pac­ity of 100 mil­lion doses on July 1.</p>
    <p>As­traZeneca has said it may be­gin de­liv­er­ing doses to Bri­tain as early as Septem­ber.</p>
    <p>“We want other com­pa­nies to have vac­cines that work as well be­cause the world will get more vac­cine sooner,” Prof Hill said.</p>
    <p>“We just feel there is an ad­van­tage of hav­ing both arms of the im­mune sys­tem stim­u­lated well.”</p>


</article>

<section>
    <h3><a href="/catalog/language/english">Newspapers in English</a></h3>
    <h3><a href="/catalog/country/singapore">Newspapers from Singapore</a></h3>
</section>

    </div>
    
    <p><a href="http://www.pressreader.com">© PressReader. All rights reserved.</a></p>

        <script>
            (function (i, s, o, g, r, a, m) {
                i['GoogleAnalyticsObject'] = r; i[r] = i[r] || function () {
                    (i[r].q = i[r].q || []).push(arguments);
                }, i[r].l = 1 * new Date();
                a = s.createElement(o), m = s.getElementsByTagName(o)[0]; a.async = 1; a.src = g;
                m.parentNode.insertBefore(a, m);
            })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
        </script>
        <script>
            ga('create', 'UA-44408245-1');
            ga('send', 'pageView');
        </script>
</body>
</html>
